{
  "disease_name": "Congenital bile acid synthesis defect type 4",
  "orpha_code": "79095",
  "drugs": [
    {
      "name": "KOLBAM",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/399979?name=79095&mode=orpha&region=",
      "regulatory_id": "399979",
      "orpha_substance_code": "ORPHA:209902",
      "details": [
        "KOLBAM(Tradename                        - 04/04/2014)Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
        "KOLBAM(Tradename                        - 04/04/2014)",
        "(Tradename                        - 04/04/2014)",
        "Disease(s) concernedORPHA:909 Cerebrotendinous xanthomatosisORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/399978?name=79095&mode=orpha&region=&status=all",
          "text": "KOLBAM",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/909",
          "text": "ORPHA:909 Cerebrotendinous xanthomatosis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79095",
          "text": "ORPHA:79095 Congenital bile acid synthesis defect type 4",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/209902",
          "text": "ORPHA:209902 Hypercholesterolemia due to cholesterol 7alpha-hydroxylase deficiency",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/399979?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Cholic acid",
      "substance_url": "/en/drug/substance/133573?name=79095&mode=orpha&region=&status=all",
      "substance_id": "133573",
      "regulatory_url": "/en/drug/regulatory/216992?name=79095&mode=orpha&region=",
      "regulatory_id": "216992",
      "orpha_substance_code": "ORPHA:79303",
      "details": [
        "Cholic acid(Medicinal product                        - 28/10/2009)Disease(s) concernedORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:79301 Congenital bile acid synthesis defect type 1ORPHA:79303 Congenital bile acid synthesis defect type 2",
        "Cholic acid(Medicinal product                        - 28/10/2009)",
        "(Medicinal product                        - 28/10/2009)",
        "Disease(s) concernedORPHA:79095 Congenital bile acid synthesis defect type 4ORPHA:79301 Congenital bile acid synthesis defect type 1ORPHA:79303 Congenital bile acid synthesis defect type 2",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/133573?name=79095&mode=orpha&region=&status=all",
          "text": "Cholic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79095",
          "text": "ORPHA:79095 Congenital bile acid synthesis defect type 4",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79301",
          "text": "ORPHA:79301 Congenital bile acid synthesis defect type 1",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79303",
          "text": "ORPHA:79303 Congenital bile acid synthesis defect type 2",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/216992?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "PLERIXAFOR ACCORD",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/642317?name=79095&mode=orpha&region=",
      "regulatory_id": "642317",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "PLERIXAFOR ACCORD(Tradename                        - 16/12/2022)",
        "(Tradename                        - 16/12/2022)",
        "Disease(s) concernedORPHA:29073 Multiple myelomaORPHA:223735 LymphomaORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/642316?name=79095&mode=orpha&region=&status=all",
          "text": "PLERIXAFOR ACCORD",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/29073",
          "text": "ORPHA:29073 Multiple myeloma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/223735",
          "text": "ORPHA:223735 Lymphoma",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/642317?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Thiotepa Riemser",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/610636?name=79095&mode=orpha&region=",
      "regulatory_id": "610636",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Thiotepa Riemser(Tradename                        - 26/03/2021)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Thiotepa Riemser(Tradename                        - 26/03/2021)",
        "(Tradename                        - 26/03/2021)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/610616?name=79095&mode=orpha&region=&status=all",
          "text": "Thiotepa Riemser",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/610636?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "VEDROP",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/213892?name=79095&mode=orpha&region=",
      "regulatory_id": "213892",
      "orpha_substance_code": "ORPHA:284385",
      "details": [
        "VEDROP(Tradename                        - 24/07/2009)Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
        "VEDROP(Tradename                        - 24/07/2009)",
        "(Tradename                        - 24/07/2009)",
        "Disease(s) concernedORPHA:52 Alagille syndromeORPHA:284385 Familial intrahepatic cholestasis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/211746?name=79095&mode=orpha&region=&status=all",
          "text": "VEDROP",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/52",
          "text": "ORPHA:52 Alagille syndrome",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/284385",
          "text": "ORPHA:284385 Familial intrahepatic cholestasis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/213892?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "ORPHA:284385 Familial intrahepatic cholestasis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 3B encoding human CYP27A1",
      "substance_url": "/en/drug/substance/686824?name=79095&mode=orpha&region=&status=all",
      "substance_id": "686824",
      "regulatory_url": "/en/drug/regulatory/686861?name=79095&mode=orpha&region=",
      "regulatory_id": "686861",
      "orpha_substance_code": "ORPHA:485631",
      "details": [
        "Adeno-associated viral vector serotype 3B encoding human CYP27A1(Medicinal product                        - 21/08/2024)Disease(s) concernedORPHA:485631 Congenital bile acid synthesis defect",
        "Adeno-associated viral vector serotype 3B encoding human CYP27A1(Medicinal product                        - 21/08/2024)",
        "(Medicinal product                        - 21/08/2024)",
        "Disease(s) concernedORPHA:485631 Congenital bile acid synthesis defect",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/686824?name=79095&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 3B encoding human CYP27A1",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/485631",
          "text": "ORPHA:485631 Congenital bile acid synthesis defect",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/686861?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "motixafortide",
      "substance_url": "/en/drug/substance/588874?name=79095&mode=orpha&region=&status=all",
      "substance_id": "588874",
      "regulatory_url": "/en/drug/regulatory/661036?name=79095&mode=orpha&region=",
      "regulatory_id": "661036",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "motixafortide(Medicinal product                        - 12/01/2024)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "motixafortide(Medicinal product                        - 12/01/2024)",
        "(Medicinal product                        - 12/01/2024)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/588874?name=79095&mode=orpha&region=&status=all",
          "text": "motixafortide",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/661036?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
      "substance_url": "/en/drug/substance/589233?name=79095&mode=orpha&region=&status=all",
      "substance_id": "589233",
      "regulatory_url": "/en/drug/regulatory/589234?name=79095&mode=orpha&region=",
      "regulatory_id": "589234",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate(Medicinal product                        - 20/04/2020)",
        "(Medicinal product                        - 20/04/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589233?name=79095&mode=orpha&region=&status=all",
          "text": "haematopoietic stem cells and blood progenitors umbilical cord-derived expanded with (1R, 4R)-N1-(2-benzyl-7-(2-methyl-2H-tetrazol-5-yl)-9H-pyrimido[4,5-b]indol-4-yl)cyclohexane-1,4-diamine dihydrobromide dihydrate",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589234?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
      "substance_url": "/en/drug/substance/589056?name=79095&mode=orpha&region=&status=all",
      "substance_id": "589056",
      "regulatory_url": "/en/drug/regulatory/589057?name=79095&mode=orpha&region=",
      "regulatory_id": "589057",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus(Medicinal product                        - 24/03/2020)",
        "(Medicinal product                        - 24/03/2020)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/589056?name=79095&mode=orpha&region=&status=all",
          "text": "Allogeneic multi-virus specific T lymphocytes targeting BK virus, cytomegalovirus, human herpesvirus-6, Epstein Barr virus and adenovirus",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/589057?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Cholic acid",
      "substance_url": "/en/drug/substance/133573?name=79095&mode=orpha&region=&status=all",
      "substance_id": "133573",
      "regulatory_url": "/en/drug/regulatory/133807?name=79095&mode=orpha&region=",
      "regulatory_id": "133807",
      "orpha_substance_code": "ORPHA:79168",
      "details": [
        "Cholic acid(Medicinal product                        - 18/12/2002)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
        "Cholic acid(Medicinal product                        - 18/12/2002)",
        "(Medicinal product                        - 18/12/2002)",
        "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/133573?name=79095&mode=orpha&region=&status=all",
          "text": "Cholic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79168",
          "text": "ORPHA:79168 Disorder of bile acid synthesis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/133807?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "CHOLBAM",
      "substance_url": null,
      "substance_id": null,
      "regulatory_url": "/en/drug/regulatory/465123?name=79095&mode=orpha&region=",
      "regulatory_id": "465123",
      "orpha_substance_code": "ORPHA:79168",
      "details": [
        "CHOLBAM(Tradename                        - 17/03/2015)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
        "CHOLBAM(Tradename                        - 17/03/2015)",
        "(Tradename                        - 17/03/2015)",
        "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/trade_name/464955?name=79095&mode=orpha&region=&status=all",
          "text": "CHOLBAM",
          "type": "trade_name_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79168",
          "text": "ORPHA:79168 Disorder of bile acid synthesis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/465123?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Tradename",
      "manufacturer": null,
      "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Adeno-associated viral vector serotype 3B encoding human CYP27A1",
      "substance_url": "/en/drug/substance/686824?name=79095&mode=orpha&region=&status=all",
      "substance_id": "686824",
      "regulatory_url": "/en/drug/regulatory/691495?name=79095&mode=orpha&region=",
      "regulatory_id": "691495",
      "orpha_substance_code": "ORPHA:485631",
      "details": [
        "Adeno-associated viral vector serotype 3B encoding human CYP27A1(Medicinal product                        - 26/11/2024)Disease(s) concernedORPHA:485631 Congenital bile acid synthesis defect",
        "Adeno-associated viral vector serotype 3B encoding human CYP27A1(Medicinal product                        - 26/11/2024)",
        "(Medicinal product                        - 26/11/2024)",
        "Disease(s) concernedORPHA:485631 Congenital bile acid synthesis defect",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/686824?name=79095&mode=orpha&region=&status=all",
          "text": "Adeno-associated viral vector serotype 3B encoding human CYP27A1",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/485631",
          "text": "ORPHA:485631 Congenital bile acid synthesis defect",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/691495?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": null,
      "regions": [
        "US"
      ]
    },
    {
      "name": "Burixafor",
      "substance_url": "/en/drug/substance/689505?name=79095&mode=orpha&region=&status=all",
      "substance_id": "689505",
      "regulatory_url": "/en/drug/regulatory/689915?name=79095&mode=orpha&region=",
      "regulatory_id": "689915",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Burixafor(Medicinal product                        - 22/10/2024)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Burixafor(Medicinal product                        - 22/10/2024)",
        "(Medicinal product                        - 22/10/2024)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/689505?name=79095&mode=orpha&region=&status=all",
          "text": "Burixafor",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/689915?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=79095&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641081?name=79095&mode=orpha&region=",
      "regulatory_id": "641081",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=79095&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641081?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Besilesomab",
      "substance_url": "/en/drug/substance/571152?name=79095&mode=orpha&region=&status=all",
      "substance_id": "571152",
      "regulatory_url": "/en/drug/regulatory/641075?name=79095&mode=orpha&region=",
      "regulatory_id": "641075",
      "orpha_substance_code": "ORPHA:506219",
      "details": [
        "Besilesomab(Medicinal product                        - 28/03/2022)Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "Besilesomab(Medicinal product                        - 28/03/2022)",
        "(Medicinal product                        - 28/03/2022)",
        "Disease(s) concernedORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/571152?name=79095&mode=orpha&region=&status=all",
          "text": "Besilesomab",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/506219",
          "text": "ORPHA:506219 Rare disorder potentially indicated for hematopoietic stem cell transplant",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/641075?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for hematopoietic stem cell transplant\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Treosulfan",
      "substance_url": "/en/drug/substance/90799?name=79095&mode=orpha&region=&status=all",
      "substance_id": "90799",
      "regulatory_url": "/en/drug/regulatory/136690?name=79095&mode=orpha&region=",
      "regulatory_id": "136690",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "Treosulfan(Medicinal product                        - 08/04/2015)Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "Treosulfan(Medicinal product                        - 08/04/2015)",
        "(Medicinal product                        - 08/04/2015)",
        "Disease(s) concernedORPHA:213500 Rare ovarian cancerORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/90799?name=79095&mode=orpha&region=&status=all",
          "text": "Treosulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/213500",
          "text": "ORPHA:213500 Rare ovarian cancer",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/136690?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "Cholic acid",
      "substance_url": "/en/drug/substance/133573?name=79095&mode=orpha&region=&status=all",
      "substance_id": "133573",
      "regulatory_url": "/en/drug/regulatory/216993?name=79095&mode=orpha&region=",
      "regulatory_id": "216993",
      "orpha_substance_code": "ORPHA:79168",
      "details": [
        "Cholic acid(Medicinal product                        - 18/07/2003)Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
        "Cholic acid(Medicinal product                        - 18/07/2003)",
        "(Medicinal product                        - 18/07/2003)",
        "Disease(s) concernedORPHA:79168 Disorder of bile acid synthesis",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/133573?name=79095&mode=orpha&region=&status=all",
          "text": "Cholic acid",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/79168",
          "text": "ORPHA:79168 Disorder of bile acid synthesis",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/216993?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "of bile acid synthesis\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    },
    {
      "name": "busulfan",
      "substance_url": "/en/drug/substance/46335?name=79095&mode=orpha&region=&status=all",
      "substance_id": "46335",
      "regulatory_url": "/en/drug/regulatory/131973?name=79095&mode=orpha&region=",
      "regulatory_id": "131973",
      "orpha_substance_code": "ORPHA:565779",
      "details": [
        "busulfan(Medicinal product                        - 21/04/1994)Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "busulfan(Medicinal product                        - 21/04/1994)",
        "(Medicinal product                        - 21/04/1994)",
        "Disease(s) concernedORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
        "More details on the regulatory status"
      ],
      "links": [
        {
          "url": "https://www.orpha.net/en/drug/substance/46335?name=79095&mode=orpha&region=&status=all",
          "text": "busulfan",
          "type": "substance_details"
        },
        {
          "url": "https://www.orpha.net/en/disease/detail/565779",
          "text": "ORPHA:565779 Rare disorder potentially indicated for transplant or complication after transplantation",
          "type": "disease_details"
        },
        {
          "url": "https://www.orpha.net/en/drug/regulatory/131973?name=79095&mode=orpha&region=",
          "text": "More details on the regulatory status",
          "type": "regulatory_status"
        }
      ],
      "status": "Medicinal product",
      "manufacturer": null,
      "indication": "potentially indicated for transplant or complication after transplantation\n                                \n\n\n\n\n\n\n            More details on the regulatory status",
      "regions": [
        "US"
      ]
    }
  ],
  "processing_timestamp": "2025-07-07T06:00:18.901776",
  "run_number": 1,
  "total_drugs_found": 18,
  "search_url": "https://www.orpha.net/en/drug?diseaseName=Congenital+bile+acid+synthesis+defect+type+4&orphaCode=79095&name=79095&region=&mode=orpha&status=all",
  "search_params": {
    "diseaseName": "Congenital bile acid synthesis defect type 4",
    "orphaCode": "79095",
    "name": "79095",
    "region": "",
    "mode": "orpha",
    "status": "all"
  }
}